Immune adverse events of checkpoint inhibitors
The current landscape for sarcoma immunotherapy treatments
Breelyn A. Wilky
What's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
Treating early stage melanoma
BRIM-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies